RORC and neoplasm: There are reports of these receptors suppressing tumour progression, e.g in MM LXRβ (Pencheva et al., 2014; Zhang, Jiang, Zhang, et al., 2014), AhR (Contador‐Troca et al., 2015) and RORα and RORγ (Brozyna et al., 2016) (note vitamin D3 hydroxy products are reverse agonists of RORα and RORγ; Slominski et al., 2017; Slominski, Kim, Takeda, et al., 2014) but they can also have a tumour promoting effect e.g. LXRβ (Nelson et al., 2013), AhR (Su et al., 2013).